Andropause
Also known as: male menopause, late-onset hypogonadism
Medically reviewed by Hormone Journal Editorial Team · Last reviewed 2026-05-22
Andropause is the gradual age-related decline in testosterone affecting roughly 10–25% of older men, also called late-onset hypogonadism or male menopause.
What it is
Andropause is the gradual, age-related decline in testosterone that affects an estimated 10–25% of older men, producing symptoms that can include fatigue, low libido, mood changes, and reduced muscle mass. Also known as late-onset hypogonadism (LOH) or colloquially as "male menopause," andropause describes a clinical syndrome in which falling testosterone levels cause measurable effects on quality of life. Testosterone typically declines at roughly 1–2% per year after age 30–40, meaning the process unfolds over decades rather than months. Not every man will notice symptoms from this decline, but for those who do — estimates suggest 20–30% of men over 50 have levels low enough to be symptomatic — the effects can touch energy, mood, body composition, sexual function, and bone density.
The term andropause is contested in medical literature. Unlike female menopause, which involves a relatively rapid and complete cessation of ovarian hormone production, testosterone decline in men is partial and variable. The Endocrine Society and other professional bodies prefer the term late-onset hypogonadism to reflect this distinction. Canadian clinicians increasingly recognize LOH as a treatable condition rather than an inevitable consequence of aging.
Causes and mechanism
The primary driver is age-related decline in testicular testosterone production, but several overlapping mechanisms contribute:
- Leydig cell loss: The Leydig cells in the testes — which synthesize testosterone — decrease in both number and function with age.
- HPG axis changes: The hypothalamic-pituitary-gonadal (HPG) axis becomes less responsive over time, with reduced pulsatile luteinizing hormone (LH) secretion that would otherwise stimulate testicular output.
- Rising SHBG: Sex hormone-binding globulin (SHBG) levels increase with age, binding more circulating testosterone and leaving less free (bioavailable) testosterone for tissues to use.
Several modifiable factors can accelerate the decline:
| Factor | Mechanism |
|---|---|
| Obesity | Aromatase in fat tissue converts testosterone to estrogen |
| Type 2 diabetes / metabolic syndrome | Insulin resistance impairs Leydig cell function |
| Obstructive sleep apnea | Disrupts nocturnal testosterone secretion |
| Opioids / glucocorticoids | Suppress HPG axis signalling |
| Chronic stress | Elevated cortisol inhibits testosterone production |
| Heavy alcohol use / smoking | Impair testicular function directly |
Treating these underlying conditions — particularly obesity and sleep apnea — can raise testosterone levels without direct hormone therapy.
Symptoms and diagnosis
Symptoms develop gradually and are often attributed to normal aging or lifestyle, which makes them easy to overlook or dismiss.
Common presentations include persistent fatigue, reduced libido, erectile dysfunction, loss of muscle mass, increased abdominal fat, low mood or irritability, difficulty concentrating, reduced body and facial hair, and sleep disturbances. None of these symptoms is specific to low testosterone; they overlap with depression, thyroid dysfunction, anemia, and other conditions.
Diagnosis requires both symptom assessment and laboratory confirmation:
- Total testosterone (morning, fasting): Tested on two separate occasions, since testosterone follows a diurnal pattern and peaks in the early morning hours.
- Free testosterone and SHBG: Gives a more accurate picture of bioavailable hormone, particularly in older men with elevated SHBG.
- LH and FSH: Distinguishes primary hypogonadism (testicular failure) from secondary hypogonadism (pituitary or hypothalamic origin).
- Metabolic panel, CBC, thyroid function: Rules out other contributors to the symptom cluster.
In Canada, testosterone testing is available through LifeLabs and Dynacare; provincial coverage for follow-up panels varies by province and clinical indication.
Treatment options
Treatment aims to restore testosterone to a functional range, address modifiable contributors, and monitor for associated health risks.
Testosterone replacement therapy (TRT) is the primary medical treatment for confirmed symptomatic testosterone deficiency. It is available in several forms — intramuscular or subcutaneous injections, transdermal gels, patches, and oral preparations — each with different dosing schedules and pharmacokinetic profiles. In appropriately selected patients, TRT improves energy, libido, body composition, mood, and bone density. Health Canada has approved several TRT formulations; a prescribing clinician can help determine which delivery method suits an individual's lifestyle and monitoring capacity.
Lifestyle modification is meaningful, particularly for men whose decline has been accelerated by obesity, poor sleep, or high alcohol intake. Resistance training, weight loss, improved sleep hygiene, and stress reduction all support endogenous testosterone production and should accompany any medical treatment.
Fertility-preserving alternatives exist for men who want to avoid TRT's suppressive effect on sperm production. Human chorionic gonadotropin (hCG) mimics LH and stimulates testicular testosterone production while maintaining fertility. Clomiphene citrate or enclomiphene stimulates the pituitary to increase LH output, raising natural testosterone without direct replacement — a useful option for younger men or those planning to conceive.
Canadian patients seeking assessment can access care through their family physician, a urologist or endocrinologist, or through virtual men's health platforms such as Felix, Phoenix, Maple, or others that offer testosterone evaluation and monitoring.
When to see a clinician in Canada
Consider booking an appointment if you are a man over 35 and are experiencing any of the following that have persisted for several months and are not explained by a recent illness or major life stressor:
- Fatigue that does not resolve with adequate sleep
- A noticeable, sustained drop in sex drive or sexual performance
- Difficulty maintaining muscle mass despite regular exercise, or progressive gain in abdominal fat
- Persistent low mood, irritability, or loss of motivation
- Worsening concentration or memory
- A low-trauma fracture, which may indicate declining bone density
A morning fasting testosterone blood test is the starting point. If results are borderline or low, a repeat test and expanded panel are typically ordered before any treatment decision is made.
Limitations and open questions
Research is still emerging on several aspects of andropause. The optimal testosterone threshold for initiating TRT in older men remains debated — different guidelines use different cut-off values, and symptoms do not always correlate neatly with measured levels. The long-term cardiovascular effects of TRT are not fully resolved; a large 2023 randomized trial (TRAVERSE) found no significant increase in major cardiovascular events in men with pre-existing cardiovascular risk, but longer follow-up data are still accumulating.
Health Canada has not issued a standalone clinical guideline on late-onset hypogonadism; Canadian clinicians generally follow Endocrine Society or Canadian Urological Association frameworks. The role of TRT in men with borderline testosterone levels and non-specific symptoms — absent a clear biochemical deficiency — remains an area of active clinical debate. Whether andropause accelerates cognitive decline or dementia risk is also unresolved, with conflicting findings across observational studies.
FAQs
Is andropause the same as menopause in men?
They share some surface similarities — both involve age-related hormonal decline and can affect mood, energy, and sexual function — but the underlying biology is quite different. Female menopause involves a rapid, complete cessation of ovarian hormone production, typically over 2–4 years. Testosterone decline in men is gradual and partial, progressing at roughly 1–2% per year over decades. Virtually all women experience menopause; only an estimated 10–25% of older men develop testosterone levels low enough to cause symptoms.
How do I know if my symptoms are from andropause or just normal aging?
A blood test is the most reliable way to find out. Fatigue, low mood, reduced libido, and changes in body composition can all stem from normal aging, depression, thyroid problems, or lifestyle factors. If these symptoms are significant and two separate morning testosterone tests confirm levels below the normal range, late-onset hypogonadism is a reasonable clinical conclusion. In Canada, initial testosterone testing is available through LifeLabs or Dynacare and is typically ordered by a family physician.
Is testosterone replacement therapy (TRT) safe?
When prescribed and monitored by a qualified clinician, TRT is considered safe for most men with confirmed testosterone deficiency. It does carry considerations: TRT suppresses natural sperm production (relevant for men who want to father children), can raise red blood cell count (polycythemia), and requires monitoring of PSA levels in men at risk for prostate issues. The 2023 TRAVERSE trial — the largest randomized study to date, involving over 5,200 men — found no significant increase in major cardiovascular events compared to placebo in men with pre-existing cardiovascular risk factors.
Can andropause be reversed with lifestyle changes alone?
Lifestyle changes can meaningfully raise testosterone, particularly when the decline has been accelerated by obesity, poor sleep, or heavy alcohol use. Studies show that losing 10% of body weight in overweight men can increase testosterone by 15–25%. However, for men with confirmed clinically significant deficiency, lifestyle changes alone are often insufficient to bring levels into a symptomatic range, and medical treatment alongside lifestyle optimization is typically needed.
Is TRT covered by provincial drug plans in Canada?
Coverage varies by province and formulation. Some injectable testosterone preparations are listed on provincial formularies and may be covered with a confirmed diagnosis of hypogonadism; topical gels and patches are less consistently covered and may require special authorization. Patients should check their provincial drug benefit program — for example, the Ontario Drug Benefit (ODB) or BC PharmaCare — and confirm coverage with their pharmacist before starting treatment, as out-of-pocket costs for non-covered formulations can range from roughly $50 to $200 per month.
Sources
- Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline
- Identification of Late-Onset Hypogonadism in Middle-Aged and Elderly Men — New England Journal of Medicine
- Andropause: Current Concepts — Indian Journal of Endocrinology and Metabolism (PMC)
- Male menopause: Myth or reality? — Mayo Clinic
- The 'male menopause' — NHS
- The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men — Journal of Clinical Endocrinology and Metabolism